rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Bio-Techne Corp

TECH · Nasdaq

Health CareLife-science toolsLeading

TECH stood above a rising 150-day average in 31 of the last 52 weekly readings, including each of the last 15 weeks. It is 15.2% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
15 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$874K
Officials’ trades on record
24

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.8M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

24 disclosed lines: House 22, Senate 1, executive 1; 7 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k27 Apr 2026filed 1 Jul 2026
April McClain Delaney House: U.S. House ClerkMD06solddependent child$1k–$15k8 Apr 2026filed 6 May 2026
April McClain Delaney House: U.S. House ClerkMD06solddependent child$1k–$15k26 Mar 2026filed 6 Apr 2026
April McClain Delaney House: U.S. House ClerkMD06solddependent child$1k–$15k24 Feb 2026filed 10 Mar 2026
April McClain Delaney House: U.S. House ClerkMD06solddependent child$1k–$15k28 Jan 2026filed 2 Feb 2026
April McClain Delaney House: U.S. House ClerkMD06boughtdependent child$1k–$15k5 Dec 2025filed 5 Jan 2026
April McClain Delaney House: U.S. House ClerkMD06boughtdependent child$1k–$15k2 Dec 2025filed 5 Jan 2026
April McClain Delaney House: U.S. House ClerkMD06boughtdependent child$1k–$15k22 Oct 2025filed 4 Nov 2025
April McClain Delaney House: U.S. House ClerkMD06solddependent child$1k–$15k1 Aug 2025filed 2 Sep 2025
April McClain Delaney House: U.S. House ClerkMD06solddependent child$1k–$15k26 May 2025filed 2 Jul 2025
April McClain Delaney House: U.S. House ClerkMD06boughtdependent child$1k–$15k29 Apr 2025filed 2 May 2025
April McClain Delaney House: U.S. House ClerkMD06boughtdependent child$1k–$15k9 Apr 2025filed 2 May 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 1
WhoDidSharesTraded
Amy E. HerrDirectorsold6,636at $48.288 May 2026filed 12 May 2026
Amy E. HerrDirectorsold1,976at $59.1117 Feb 2026filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

John L. Higgins Company insiderDirector · last 28 Sep 20260 · 10
Robert Baumgartner V Company insiderDirector · last 22 Sep 20265 · 16
Amy E. Herr Company insiderDirector · last 17 Aug 20260 · 4
James Hippel Company insiderCFO · last 17 Aug 20260 · 19
Kim Kelderman Company insiderChief Executive Officer · last 17 Aug 20260 · 6
Shane Bohnen Company insiderSVP - General Counsel · last 17 Aug 20260 · 0
Steven C. Crouse Company insiderPresident - Diag & Spatial Bi · last 17 Aug 20260 · 0
William Geist Company insiderPRESIDENT, PROTEIN SCIENCES · last 17 Aug 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 27 Apr 20260 · 1
April McClain Delaney HouseMD06 · last 8 Apr 20265 · 6
Matthew McManus Company insiderPresident - Diag & Spatial Bio · last 1 Feb 20260 · 0
Alpna Seth Company insiderDirector · last 30 Oct 20250 · 1

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2026 · to 30 Jun 202665.8%
Operating profit marginFY 2026 · to 30 Jun 202620.7%
Free cash flow marginFY 2026 · to 30 Jun 202621.7%
Return on capital employedFY 2026 · to 30 Jun 202610.4%
Share count trendFY 2026 · to 17 Aug 20260.5%
Cash and equivalentsFY 2026 · to 30 Jun 2026$264.7M
Free cash flowFY 2026 · to 30 Jun 2026$263.2M

Analyst forecasts

No analyst forecasts yet.